Beigene Signs Exclusive License and Development Agreement with Zymeworks (ZW)

Shots:

• Beigene to get exclusive development and commercialization rights to ZW’s ZW25 and ZW49 candidates in Asia, New Zealand and Australia (ex. Japan). ZW to receive $40M upfront, $390M milestones and tiered royalties on sales
• Also, Beigene to get WW rights of ZW’s Azymetric & EFECT platforms, to develop up to three bispecific Abs and ZW to receive $20M upfront, $702M milestone plus royalties on global sales
• ZW49 is a bispecific pre-clinical candidate targeting two non-overlapping epitopes of HER2. ZW25 is a P-I candidate developed using Azymetric platform, used for binding two non-overlapping epitopes of HER2

Click here to read full press release/ article | Ref: Zymeworks | Image: PMLive